Pioneering Cancer Research
Ixogen patented technology uses genetically modified Adenoviruses to target tumours by replicating and killing cancer cells through lysis while predominantly leaving normal cells intact.
The future of cancer treatments
Through developing and patenting a portfolio of powerful oncolytic Adenoviruses, able to target and kill solid cancers, while stimulating secondary immunological cancer fighting mechanisms, our goal is to advance our portfolio of treatments into phase 1 clinical trials.
“A new stable, safe and powerful oncolytic virus, offers new hope for cancer patients.”
Founder: Ghassan Alusi